睿知中国医院研究地图
候选清单

正在招募胰腺癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由北京协和医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)北京协和医院Peking Union Medical College Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06353646,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma;

    入选标准第 3 条

    Completed an R0 or R1 surgical resection as determined by pathology;

    入选标准第 4 条

  3. Received immunomodulatory medications within 4 weeks prior to the date of the first dose (D1) of XH001, including but not limited to: IL-2, CTLA-4 inhibitors, CD40 agonists, CD137 agonists, IFN-α;

    排除标准第 9 条

  4. ECOG score is 0 or 1;

    入选标准第 6 条

  5. Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.

    入选标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06353646,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Provision of signed and dated informed consent form;
  2. Aged 18 to 75 years old;
  3. Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma;
  4. Completed an R0 or R1 surgical resection as determined by pathology;
  5. Have not received any prior neoadjuvant therapy;
  6. ECOG score is 0 or 1;
  7. Life expectancy of greater than 12 months;
  8. CA19-9 <100U/mL before initial chemotherapy;
  9. Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.
  10. Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.

排除标准:Exclusion Criteria:

  1. Borderline resectable pancreatic cancer;
  2. Evidence of disease recurrence or metastasis following surgical resection at any time;
  3. Evidence of malignant ascites;
  4. Pre-existing inflammatory bowel disease or the presence of complete or partial bowel obstruction, or persistent severe diarrhea after surgery;
  5. Needs to receive long-term systemic anti-allergic drug or known hypersensitivity to any component of the study treatment;
  6. History of autoimmune disease;
  7. New cerebrovascular accident (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack) within 6 months before screening;
  8. Acute myocardial infarction within 6 months before screening, or uncontrolled angina, uncontrolled arrhythmia, severe heart failure (see Appendix 3, New York Heart Association Heart Failure Classification Criteria NYHA Class ≥ III) and other cardiovascular diseases;
  9. Received immunomodulatory medications within 4 weeks prior to the date of the first dose (D1) of XH001, including but not limited to: IL-2, CTLA-4 inhibitors, CD40 agonists, CD137 agonists, IFN-α;
  10. Received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 7 days prior to the first dose of XH001;
  11. Received therapeutic tumor vaccines;
  12. With congenital or acquired immunodeficiency;
  13. Participating in other clinical trials and had not withdrawn during screening period;
  14. Unable or unwilling to comply with the study protocol due to potential health, mental or social conditions in the opinion of the investigator;
  15. Other conditions that, in the opinion of the investigator, would make participation in this study inappropriate.

引自 ClinicalTrials.gov, NCT06353646, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06353646,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06353646